IFNG and tuberous sclerosis: There are recent preclinical studies using mouse models of TSC related tumors that indicate other approved drugs (such as angiogenesis inhibitors, interferon-gamma, asparaginase) may have potential therapeutic utility as single agents or in combination with mTOR inhibitors [15], [17], [53], [54].